[1] Berzigotti A,Seijo S,Reverter E,et al.Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol,2013,7(2):141-155. [2] Pan M,Cai XY,Bang-Yu LU,et al.The clinical research of laparoscopic modified sugiura procedure for the treatment of portal hypertension. China J Endosc,2013,19(12):1287-1290. [3] Schettini AV,Pinheiro RS,Pescatore P,et al.Modified sugiura operation for idiopathic portal hypertension with bleeding oesophageal varices: A case report. Acta Chir Belg,2015,115(3):237-240. [4] Puljic A,Salati J,Doss A,et al.Outcomes of pregnancies complicated by liver cirrhosis,portal hypertension,or esophageal varices. J Matern Fetal Neonatal Med,2016,29(3):506-509. [5] Anikina EV,Kovtun AV,Iakovenko AV,et al.Disorders of gut microflora in the pathogenesis of liver cirrhosis and complications of portal hypertension. Eksp Klin Gastroenterol,2014(12):20-23. [6] 赵超占,曾辉,吴建军,等. 超声检查诊断肝硬化并发门脉高压症临床价值研究. 实用肝脏病杂志,2016,19(4):455-458. [7] Khan AU,Irfanullah J,Shah SQ,et al.99mTc-phytate transsplenic portal scintigraphy in the diagnosis of cirrhotic portal hypertension and compensatory circulation. Abdom Imaging,2015,40(2):258-264. [8] 李晓东,郑本波,刘山. 脾切除联合贲门周围血管离断术治疗肝硬化并发门脉高压症患者血细胞和肝功能的变化. 实用肝脏病杂志,2018,21(2):289-290. [9] Yao BN.Observation on the curative effect of selective pericardial devascularization in the treatment of cirrhotic portal hypertension. Foot Ankle Int,2015,16(1):51-56. [10] Mercado MA.Surgical treatment for portal hypertension. Br J Surg,2015,102(7):717-718. [11] Sun H.Clinical study on treatment of liver cirrhosis with portal hypertension. J Antimicrob Chemother,2014,34(9):10-11. [12] 郑万明,童登武. 改良的Sugiura术治疗肝硬化并发门脉高压症临床疗效观察. 中国伤残医学,2014,12(1):65-66. [13] 褚海波,徐睿. 门脉高压症血流动力学代偿机制探讨. 腹部外科,2014,27(6):460-462. [14] Berzigotti A,Seijo S,Reverter E,et al.Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol,2013,7(2):141-155. [15] Cho E,Jun CH,Cho SB,et al.Endoscopic variceal ligation-induced ulcer bleeding:What are the risk factors and treatment strategies Medicine (Baltimore),2017,96(24):e7157. [16] Peng Y,Qi XS,Guo XZ.Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis:A systematic review and Meta-analysis of observational studies. Medicine (Baltimore),2016,95(8):e2877. [17] Li J,Hu SB,Wang LY,et al.Autophagy-dependent generation of Axin2+ cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis. Oncogene,2017,36(48):6725-6737. [18] Zhang LL,Zhang HY,Lv ML,et al.Increased expression of 78 kD glucose-regulated protein promotes cardiomyocyte apoptosis in a rat model of liver cirrhosis. Int J Clin Exp Pathol,2015,8(8):9256-9263. [19] Gao B,Zhang XM,Huang YM,et al.Coding and non-coding gene regulatory networks underlie the immune response in liver cirrhosis. PLoS One,2017,12(3):e0174142. [20] Buechler C,Haberl EM,Rein-Fischboeck L,et al.A dipokines in liver cirrhosis. Int J Mol Sci,2017,18(7):1392. [21] Lee S,Kim DY.Non-invasive diagnosis of hepatitis B virus-related cirrhosis. World J Gastroenterol,2014,20(2):445-459. [22] Mokdad AA,Lopez AD,Shahraz S,et al.Liver cirrhosis mortality in 187 countries between 1980 and 2010:a systematic analysis. BMC Med,2014,12:145. [23] Kang W,Kim SU,Ahn SH.Non-invasive prediction of forthcoming cirrhosis-related complications. World J Gastroenterol,2014,20(10):2613-2623. [24] Dai JN,Qi XS,Li HY,et al.Role of D-dimer in the development of portal vein thrombosis in liver cirrhosis:A Meta-analysis. Saudi J Gastroenterol,2015,21(3):165-174. [25] Zhu CH,Qi XS,Li HY,et al.Correlation of serum liver fibrosis markers with severity of liver dysfunction in liver cirrhosis:a retrospective cross-sectional study. Int J Clin Exp Med,2015,8(4):5989-5998. |